The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Randomized Phase II Study Comparing Gemcitabine Plus Dacarbazine Versus Dacarbazine Alone in Patients With Previously Treated Soft Tissue Sarcoma: A Spanish Group for Research on Sarcomas Study
Abstract
Purpose: To assess the activity and toxicity of the combination of gemcitabine plus dacarbazine (DTIC) in patients with advanced soft tissue sarcoma (STS) in a randomized, multicenter, phase II study using DTIC alone as a control arm. Patients and Methods: Patients with previously treated advanced STS were randomly assigned to receive either fixed-dose rate gemcitabine (10 mg/m 2 /min) at 1,800 mg/m 2 followed by DTIC at 500 mg/m 2 every 2 weeks, or DTIC alone at 1,200 mg/m 2 every 3 weeks. The primary end point of the study was progression-free rate (PFR) at 3 months. Results: From November 2005 to September 2008, 113 patients were included. PFR at 3 months was 56% for gemcitabine plus DTIC versus 37% for DTIC alone (P = .001). Median progression-free survival was 4.2 months versus 2 months (hazard ratio [HR], 0.58; 95% CI, 0.39 to 0.86; P = .005), and median overall survival was 16.8 months versus 8.2 months (HR, 0.56; 95% CI, 0.36 to 0.90; P = .014); both favored the arm of gemcitabine plus DTIC. Gemcitabine plus DTIC was also associated with a higher objective response or higher stable disease rate than was DTIC alone (49% v 25%; P = .009). Severe toxicities were uncommon, and treatment discontinuation for toxicity was rare. Granulocytopenia was the more common serious adverse event, but febrile neutropenia was uncommon. Asthenia, emesis, and stomatitis were the most frequent nonhematologic effects. Conclusion: The combination of gemcitabine and DTIC is active and well tolerated in patients with STS, providing in this phase II randomized trial superior progression-free survival and overall survival than DTIC alone. This regimen constitutes a valuable therapeutic alternative for these patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maki, R. G., Wathen, J. K., Patel, S. R., Priebat, D. A., Okuno, S. H., Samuels, B., Fanucchi, M., Harmon, D. C., Schuetze, S. M., Reinke, D., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.4117 · Cited by 742
Van Glabbeke, M., van Oosterom, A. T., Oosterhuis, J. W., Mouridsen, H., Crowther, D., Somers, R., Verweij, J., Santoro, A., Buesa, J., & Tursz, T. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.150 · Cited by 608
Self-citationDemetri, G. D., Chawla, S. P., von Mehren, M., Ritch, P., Baker, L. H., Blay, J. Y., Hande, K. R., Keohan, M. L., Samuels, B. L., Schuetze, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.0088 · Cited by 538
Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas
Van Glabbeke, M., Verweij, J., Judson, I., & Nielsen, O. S. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00398-7 · Cited by 424
Localized Extremity Soft Tissue Sarcoma: Improved Knowledge With Unchanged Survival Over Time
Weitz, J., Antonescu, C. R., & Brennan, M. F. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.026 · Cited by 365
Patel, S. R., Gandhi, V., Jenkins, J., Papadopolous, N., Burgess, M. A., Plager, C., Plunkett, W., & Benjamin, R. S. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.15.3483 · Cited by 247
Sleijfer, S., Ouali, M., van Glabbeke, M., Krarup-Hansen, A., Rodenhuis, S., Le Cesne, A., Hogendoorn, P. C. W., Verweij, J., & Blay, J.-Y. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2009.09.022 · Cited by 244
Leu, K. M., Ostruszka, L. J., Shewach, D., Zalupski, M., Sondak, V., Biermann, J. S., Lee, J. S.-J., Couwlier, C., Palazzolo, K., & Baker, L. H. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.043 · Cited by 241
Verweij, J., Lee, S. M., Ruka, W., Buesa, J., Coleman, R., van Hoessel, R., Seynaeve, C., di Paola, E. D., van Glabbeke, M., Tonelli, D., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.10.2081 · Cited by 171
Self-citationdel Muro, X. G., Pousa, A. L., Martín‐Broto, J., Buesa, J., Martínez‐Trufero, J., Casado, A., Poveda, A. M., Cruz, J., Bover, I., & Maurel, J. (2005) · Cancer · doi:10.1002/cncr.21384 · Cited by 94
Self-citation
Cited by
van der Graaf, W. T., Blay, J.-Y., Chawla, S. P., Kim, D.-W., Bui-Nguyen, B., Casali, P. G., Schöffski, P., Aglietta, M., Staddon, A. P., Beppu, Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60651-5 · Cited by 2,102
Casali, P. G., Abecassis, N., Bauer, S., Biagini, R., Bielack, S., Bonvalot, S., Boukovinas, I., Bovee, J. V. M. G., Brodowicz, T., Broto, J. M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy096 · Cited by 1,614
Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
von Mehren, M., Kane, J. M., Agulnik, M., Bui, M. M., Carr-Ascher, J., Choy, E., Connelly, M., Dry, S., Ganjoo, K. N., Gonzalez, R. J., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0035 · Cited by 1,182
Gronchi, A., Miah, A. B., Dei Tos, A. P., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R., Bielack, S., Blay, J. Y., Bolle, S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.07.006 · Cited by 1,115
Demetri, G. D., von Mehren, M., Jones, R. L., Hensley, M. L., Schuetze, S. M., Staddon, A., Milhem, M., Elias, A., Ganjoo, K., Tawbi, H., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.4734 · Cited by 841
Metadata
- Authors
- García-del-Muro, X., López-Pousa, A., Maurel, J., Martín, J., Martínez-Trufero, J., Casado, A., Gómez-España, A., Fra, J., Cruz, J., Poveda, A., Meana, A., Pericay, C., Cubedo, R., Rubió, J., De Juan, A., Laínez, N., Carrasco, J. A., de Andrés, R., & Buesa, J. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-06-20
- Volume
- 29
- Issue
- 18
- Pages
- 2528-2533
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2151384475
- Cited by
- 307
- References
- 11
- FWCI
- 11.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized Phase II Study Comparing Gemcitabine Plus Dacarbazine Versus Dacarbazine Alone in Patients With Previously Treated Soft Tissue Sarcoma: A Spanish Group for Research on Sarcomas Study. https://app.cochat.ai/papers/10.1200/jco.2010.33.6107
- The paper
- García-del-Muro, X., López-Pousa, A., Maurel, J., Martín, J., Martínez-Trufero, J., Casado, A., Gómez-España, A., Fra, J., Cruz, J., Poveda, A., Meana, A., Pericay, C., Cubedo, R., Rubió, J., De Juan, A., Laínez, N., Carrasco, J. A., de Andrés, R., & Buesa, J. M. (2011). Randomized Phase II Study Comparing Gemcitabine Plus Dacarbazine Versus Dacarbazine Alone in Patients With Previously Treated Soft Tissue Sarcoma: A Spanish Group for Research on Sarcomas Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2010.33.6107
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.